newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450

  • AEON Biopharma submitted an Investigational New Drug (IND) application to the FDA for a comparative pharmacodynamic study of ABP-450 using compound muscle action potential (CMAP) measurements.
  • The submission follows a recent FDA Type 2b meeting & advances the Company's strategy to build a totality-of-evidence package under the 351(k) biosimilar regulatory pathway.
  • The planned CMAP study aims to generate objective clinical evidence comparing the neuromuscular activity of ABP-450 & BOTOX®, with study initiation expected in Q1 2027.
  • AEON intends to use this sensitive pharmacodynamic data to support a biosimilar Biologics License Application (BLA) without necessarily requiring a standalone comparative clinical efficacy study.
  • ABP-450 is the same botulinum toxin complex marketed by Evolus, Inc. for cosmetic indications under the name Jeuveau®.
  • AEON holds exclusive development & distribution rights for ABP-450 therapeutic indications in the U.S., Canada, the EU, the UK, & other international territories.
  • The manufacturing facility for ABP-450 is authorized by the FDA, Health Canada, & the European Medicines Agency.